Skip to content

Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1509-1516
Number of pages8
JournalJournal of Veterinary Internal Medicine
Issue number5
Early online date14 Sep 2018
DateAccepted/In press - 3 May 2018
DateE-pub ahead of print - 14 Sep 2018
DatePublished (current) - 14 Sep 2018


Background: Therapy targeted to achieve reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) improves outcomes in human congestive heart failure (CHF) patients. Hypothesis: A pre-specified therapeutic algorithm that increased diuretic or pimobendan usage will reduce plasma NT-proBNP concentrations in dogs with CHF secondary to myxomatous mitral valve disease (MMVD). Animals: Twenty-six dogs with clinically stable CHF secondary to MMVD. Methods: Prospective, controlled before-and-after study. Dogs were examined up to 3 times over 21 days. Treatment was prescribed based on NT-proBNP as follows: <1500 pmol/L at baseline, no therapy adjustment at any point during the study (group 1); ≥1500 pmol/L and creatinine ≤3.0 mg/dL at baseline or subsequent visits, therapy escalated according to the algorithm (group 2); ≥1500 pmol/L at baseline, no therapy adjustment (group 3). Results: NT-proBNP decreased significantly in group 2 (mean change=-1,736 pmol/L (95% CI, -804 to -2,668), P<0.001) but not in groups 1 or 3 (623 pmol/L (-631 to 1877 pmol/L), P=0.14 and 685 pmol/L (-304 to 1068 pmol/L), P=0.46, respectively). Serum BUN and creatinine did not change significantly between visit 0 and visit 2 in group 1 (median=23 mg/dL (range 13-32) vs. 19 mg/dL (12-38), P=0.72 and1.15 mg/dL (0.70 – 1.40) vs. 0.95 mg/dL (0.70 – 1.10), P=0.10, respectively) or group 2 (28 mg/dL (18-87) vs. 43.5 mg/dL (21-160), P=0.092 and 1.10 mg/dL (0.90 – 2.50) vs.1.55 mg/dL (0.90 – 3.30), P=0.062, respectively). Conclusions and clinical importance: Use of this treatment escalation algorithm allows effective targeting of therapy for CHF in dogs against an objective criterion.

    Research areas

  • Biomarker, Treatment, Canine, Endocardiosis

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Wiley at Please refer to any applicable terms of use of the publisher.

    Final published version, 699 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups